Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Researchers conducted a review of literature to determine whether chemotherapy and endocrine therapy for breast cancer are associated with cognitive impairments in patients.
Tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved patient survival outcomes. Get comprehensive information on…
Cancer Survivor Statistics There are an estimated 18.1 million cancer survivors in the United States. This represents approximately 5.4% of the population. The number of…
According to Ashley L. Sumrall, MD, there’s not a great deal of difference between a practicing oncologist and a physician advocate.“As healthcare providers, we spend…
8592 Background: SG, a Trop-2–directed antibody-drug conjugate, has clinical activity and manageable safety in heavily pretreated patients with mNSCLC. EVOKE-02 (NCT05186974) is an ongoing, global,…
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
The OncoAlert Newsletter is now out for June 23-29, 2023
Retreatment with daratumumab showed response rates similar to overall response rates from initial daratumumab-based regimens in a retrospective study.
Format focusing on your clinical practice – Get a full update on prostate cancer, in a multidisciplinary and international setting.
Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.